Westfield Capital Management
BCYC

Westfield Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Westfield Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,016,026
Closed -$21.4M – 254
2025
Q4 		$21.4M Buy
3,016,026
+63,483
+2% +$468K 0.09% 176
2025
Q3 		$22.9M Buy
2,952,543
+172,052
+6% +$1.3M 0.1% 178
2025
Q2 		$19.3M Buy
2,780,491
+123,186
+5% +$981K 0.08% 181
2025
Q1 		$22.6M Buy
2,657,305
+46,968
+2% +$553K 0.11% 169
2024
Q4 		$36.5M Buy
2,610,337
+759,392
+41% +$16.3M 0.16% 162
2024
Q3 		$41.9M Buy
1,850,945
+327,089
+21% +$7.55M 0.19% 145
2024
Q2 		$30.8M Buy
1,523,856
+484,939
+47% +$11M 0.15% 172
2024
Q1 		$25.9M Buy
1,038,917
+121,613
+13% +$2.58M 0.14% 179
2023
Q4 		$16.6M Buy
+917,304
New +$15.2M 0.1% 182

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
GP
GSK plc London $602M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Westfield Capital Management's BCYC Position: Q1 2026 in Review

Westfield Capital Management sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 3,016,026 shares — an estimated $21.4M sold.

Westfield Capital Management first reported a position in BCYC in Q4 2023 and held it in 9 quarters. The position peaked at $41.9M in Q3 2024. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Westfield Capital Management reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Westfield Capital Management sold 3,016,026 Bicycle Therapeutics shares in Q1 2026, an estimated $21.4M.
  • Westfield Capital Management first reported a position in Bicycle Therapeutics in Q4 2023 and held it in 9 quarters.
  • Westfield Capital Management's Bicycle Therapeutics position peaked at $41.9M in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Westfield Capital Management's 13F filing for Q1 2026, filed 11 May 2026.